



Company Contact:
Jie Du, Ph.D.
President & CEO
JDP THERAPEUTICS, INC.
Tel: 215-661-8557
Email: jjedu@jdptherapeutics.com
www.jdptherapeutics.com

JDP Announces Appointment of Chief Operating Officer

LANSDALE, PENNSYLVANIA, July 19, 2011 – JDP Therapeutics Inc., a privately held specialty pharmaceutical company, today announced that Kumaril Bhargava, Ph.D., MBA, has joined JDP Therapeutics as its Chief Operating Officer. Dr. Bhargava brings a wealth of pharmaceutical experience expanding more than twenty years in leading both the Drug Development and Commercial groups in large pharmaceutical companies including Procter & Gamble, Abbott, J&J and Pfizer. Prior to joining JDP Therapeutics, Dr. Bhargava led the Strategic Innovation in the External Research & Development group at Pfizer, and served as the Director of New Business and Strategy at Wyeth. Dr. Bhargava holds a Ph.D. in Pharmacy from Philadelphia College of Pharmacy & Science and an MBA from University of Chicago in Finance and Strategy.

"We are delighted to have Dr. Bhargava join us as our Chief Operating Officer", said Jie Du, Ph.D., President and CEO at JDP Therapeutics. "Kumaril's deep pharmaceutical development and commercial expertise combined with his extensive management and regulatory experiences, represents a significant addition to our leadership capabilities. With Kumaril's addition to our team, we have great confidence in our ability to execute on our aggressive growth objectives. We welcome Kumaril to the Company and look forward to his contribution to the future development of JDP and its clinical programs".

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.